ChemoMetec Upgrades 2026/27 Financial Guidance and Reports Preliminary Q1 Results

ChemoMetec raised its 2026/27 guidance, citing stronger-than-expected demand for its instruments, particularly the NC-203, and a lower cost base. It now expects revenue of DKK 570–605 million, up from DKK 560–590 million, and EBITDA of DKK 335–360 million, compared with DKK 330–345 million previously. Preliminary first-quarter revenue was DKK 160.0 million, up 28% year over year, while EBITDA reached DKK 100.3 million, a 63% margin.